APA (7th ed.) Citation

BK, G., EM, M., J, S., J, R., A, P., D, D. R., . . . JA, W. (2026). PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia. Blood cancer discovery, 7(1), 85. https://doi.org/10.1158/2643-3230.BCD-25-0114

Chicago Style (17th ed.) Citation

BK, Gordon, et al. "PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia." Blood Cancer Discovery 7, no. 1 (2026): 85. https://doi.org/10.1158/2643-3230.BCD-25-0114.

MLA (9th ed.) Citation

BK, Gordon, et al. "PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor-Resistant Chronic Lymphocytic Leukemia." Blood Cancer Discovery, vol. 7, no. 1, 2026, p. 85, https://doi.org/10.1158/2643-3230.BCD-25-0114.